|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
134,000,000 |
Market
Cap: |
N/A |
Last
Volume: |
1,528,949 |
Avg
Vol: |
715,891 |
52
Week Range: |
$24.45 - $24.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Novartis Ag |
10% Owner |
|
2014-08-05 |
4 |
D |
$24.50 |
$816,356,513 |
D/D |
(33,320,674) |
0 |
|
- |
|
Klarman Seth A |
10% Owner |
|
2014-08-05 |
4 |
D |
$24.50 |
$1,306,612,171 |
I/I |
(53,331,109) |
0 |
|
- |
|
Renaud Ronald C Jr |
President & CEO |
|
2014-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
89,990 |
89,990 |
|
- |
|
Renaud Ronald C Jr |
President & CEO |
|
2014-06-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
89,990 |
0 |
|
- |
|
Klarman Seth A |
10% Owner |
|
2014-01-31 |
4 |
B |
$6.50 |
$106,731,567 |
I/I |
16,420,241 |
53,331,109 |
1.5 |
- |
|
Klarman Seth A |
10% Owner |
|
2013-11-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
36,910,868 |
|
- |
|
Renaud Ronald C Jr |
President & CEO |
|
2012-12-14 |
4 |
OE |
$2.41 |
$199,976 |
D/D |
74,990 |
89,990 |
|
- |
|
Fanning Paul |
SVP, Human Resources |
|
2012-03-16 |
4 |
S |
$11.04 |
$331,200 |
D/D |
(30,000) |
1,300 |
|
- |
|
Fanning Paul |
SVP, Human Resources |
|
2012-03-16 |
4 |
OE |
$2.41 |
$72,300 |
D/D |
30,000 |
31,300 |
|
- |
|
Novartis Pharma Ag |
Indirect 10% Owner |
|
2012-02-23 |
4 |
B |
$2.41 |
$291,283 |
I/I |
84,893 |
33,320,674 |
1.5 |
- |
|
Novartis Pharma Ag |
Indirect 10% Owner |
|
2011-11-22 |
4 |
B |
$2.41 |
$206,400 |
I/I |
50,530 |
33,235,781 |
1.5 |
- |
|
Brookside Capital Investors Ii, L.p. |
10% Owner |
|
2011-10-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,987,500 |
|
- |
|
Novartis Pharma Ag |
Indirect 10% Owner |
|
2011-04-13 |
4 |
B |
$2.80 |
$4,999,999 |
I/I |
1,785,714 |
33,185,191 |
1.5 |
- |
|
Novartis Pharma Ag |
Indirect 10% Owner |
|
2011-02-25 |
4 |
B |
$2.41 |
$55,417 |
I/I |
20,993 |
31,399,477 |
1.5 |
- |
|
Novartis Pharma Ag |
Indirect 10% Owner |
|
2010-11-26 |
4 |
B |
$2.41 |
$46,690 |
I/I |
17,083 |
31,378,484 |
1.5 |
- |
|
Novartis Pharma Ag |
Indirect 10% Owner |
|
2010-08-23 |
4 |
B |
$2.41 |
$91,009 |
I/I |
37,214 |
31,361,401 |
1.5 |
- |
|
Novartis Pharma Ag |
10% owner |
|
2010-08-13 |
4/A |
B |
$2.41 |
$91,009 |
I/I |
37,214 |
31,361,401 |
1.5 |
- |
|
Novartis Pharma Ag |
Indirect 10% Owner |
|
2010-06-08 |
4 |
B |
$2.41 |
$3,256 |
I/I |
1,351 |
31,324,187 |
1.42 |
- |
|
Novartis Pharma Ag |
Indirect 10% Owner |
|
2010-02-26 |
4 |
B |
$2.41 |
$4,512 |
I/I |
1,872 |
31,322,836 |
1.42 |
- |
|
Hodgson Thomas R |
Director |
|
2009-12-16 |
4 |
B |
$2.12 |
$22,020 |
I/I |
10,387 |
57,200 |
2.1 |
- |
|
Hodgson Thomas R |
Director |
|
2009-12-15 |
4 |
B |
$2.15 |
$32,250 |
I/I |
15,000 |
46,813 |
2.1 |
- |
|
Hodgson Thomas R |
Director |
|
2009-12-14 |
4 |
B |
$2.12 |
$23,320 |
I/I |
11,000 |
31,813 |
2.1 |
- |
|
Hodgson Thomas R |
Director |
|
2009-12-11 |
4 |
B |
$2.08 |
$17,915 |
I/I |
8,613 |
20,813 |
2.1 |
- |
|
Hodgson Thomas R |
Director |
|
2009-12-10 |
4 |
B |
$2.05 |
$10,250 |
I/I |
5,000 |
12,200 |
2.1 |
- |
|
Weidenbruch John |
Ex. VP, Gen. Counsel and Secr. |
|
2009-11-24 |
4 |
B |
$1.89 |
$37,800 |
D/D |
20,000 |
35,000 |
2.74 |
- |
|
77 Records found
|
|
Page 1 of 4 |
|
|